Daily Archives: Dezembro 16, 2021 | LinksMedicus Free Medical News & Perspectives

Modelagem da mortalidade por COVID-19 em 44 países: uso de máscaras pode reduzir as mortes.

16 Dez, 2021 | 13:08h

Modeling COVID-19 Mortality Across 44 Countries: Face Covering May Reduce Deaths – American Journal of Preventive Medicine

Comentário: Mask laws could prevent unnecessary COVID-19 deaths, study shows – News Medical

Revisão revela que as diretrizes sobre Covid são baseadas em evidências fracas.

16 Dez, 2021 | 13:05h

Review uncovers weak COVID clinical practice guidelines – CIDRAP

Estudo original: Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards: A Systematic Review – JAMA Network Open

Comentário no Twitter

This systematic review found that few clinical practice guidelines for pharmacologic treatment of hospitalized patients with #COVID19 met the National Academy of Medicine standards for trustworthy guidelines. https://t.co/nOCDp4pJWx

— JAMA Network Open (@JAMANetworkOpen) December 10, 2021

Medicamento da Merck contra COVID perde seu brilho: o que isso significa para a pandemia – “Molnupiravir foi inicialmente anunciado pelos oficiais de saúde pública como um elemento que mudaria o cenário da COVID-19, mas dados finais dos estudos clínicos mostraram eficácia abaixo das expectativas.”

16 Dez, 2021 | 13:04h

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Conteúdos relacionados:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Opinião | Cobertura vacinal desigual no mundo é o centro da atual crise da Covid-19.

16 Dez, 2021 | 13:02h

Unequal global vaccine coverage is at the heart of the current covid-19 crisis – The BMJ

Encefalite autoimune após infecção por SARS-CoV-2: frequência de casos, achados e desfechos.

16 Dez, 2021 | 13:01h

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes – Neurology

Comentário no Twitter

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes https://t.co/KIKzlf3hev #COVID #Neurology pic.twitter.com/q2Qf7NeJHo

— Neurology Journal (@GreenJournal) December 11, 2021